Osteogenic potency of stem cell-based genetic engineering targeting Wnt3a and Wnt9a
Open Life Sciences
AbstractBone engineering is a promising therapeutic approach to correct skeletal defects, and genetically-modified stem cells have been implicated in engineering new bone. However, the use of genetically-modified human mesenchymal stem cells targeting an osteogenic growth factor Wnt is not yet investigated. In the present study, a proliferation assay and the alkaline phosphatase (ALP) activity and expression of runt-related transcription factor 2 (Runx2) and osteocalcin (OC) transcripts were
... transcripts were investigated to examine the effect of Wnt2 overexpression, Wnt3a overexpression, and Wnt9a knockdown on cell proliferation and osteoblast differentiation of bone marrowderived mesenchymal stem cells (BMSCs). The results showed that the expression of Wnt2 and Wnt3a was up-regulated throughout the osteoblast differentiation period of BMSCs, whereas that of Wnt9a was down-regulated. Overexpression of Wnt3a stimulated cell proliferation while knockdown of Wnt9a increased the ALP activity and the expression of Runx2 and OC. Double transfection producing Wnt3a overexpression and Wnt9a knockdown simultaneously resulted in up-regulation of osteoblast differentiation markers, i.e., the ALP activity and the Runx2 expression. In conclusion, simultaneous genetic modification of Wnt3a overexpression and Wnt9a knockdown enhances osteoblast differentiation of BMSCs, suggesting its osteogenic potency to regenerate new bone in vivo.